Recurrent Prostate Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

After initial surgery, radiation therapy, and/or hormone therapy, prostate cancer can come back and require further treatment. The body's other parts or the prostate itself may experience a recurrence of prostate cancer. Third most common cancer is prostate cancer. It is an extremely diverse illness, with a global incidence of 6 to 83 per 100,000 people. The most frequent form of radiation treatment for prostate cancer recurrence is external radiation therapy. It is compatible with hormonal therapy. Radiation therapy may be used to treat prostate cancer that has already undergone surgery but has returned to the same location. External beam radiation cannot be used to treat the same area of cancer if it has already been exposed to it.

Description

After initial surgery, radiation therapy, and/or hormone therapy, prostate cancer can return. This is known as recurrent prostate cancer. In the area directly surrounding the prostate or elsewhere in the body, prostate cancer can return. It is frequently unsafe to administer another radiation treatment to the same area after a patient has received radiation therapy to the prostate. For patients, whose prostate cancer has returned following initial radiotherapy, systemic therapy with ADT is the mainstay of treatment. Because the prostate cancer continues even after radiation therapy, surgeons rarely remove the prostate. The prostate is fixed with a catheter during cryosurgery, a focused treatment used by other surgeons. Patients who have previously undergone radiation therapy, however, are more likely to experience complications following surgery or cryosurgery. if the patient is receiving other systemic treatments, such as chemotherapy or immunotherapy, or if they are not a good candidate for such local treatment. Decisions regarding additional treatment are made in part based on whether or not the cancer has spread (metastasized) to other body parts if prostate cancer returns after initial treatment with a prostatectomy. Radiation therapy can be used to treat cancer that is limited to the prostate area, either in combination with or without androgen deprivation therapy (ADT). ADT, which can be used with or without radiotherapy, is the primary strategy if it is believed that the cancer has spread to other parts of the body. Reducing levels of male hormones like testosterone allows ADT to slow or stop the growth of cancer. ADT can typically control recurrent prostate cancer for a while, typically several years. At the end of the day, however, the majority of prostate cancers still progress. As it has been demonstrated that chemotherapy increases survival, it is also being used more frequently in men with recurrent prostate cancer that has spread outside of the prostate area. After the initial course of treatment, PSA levels should be carefully watched. If the PSA starts to increase after dropping to zero or close to zero, it might mean that the prostate cancer has come back. The detection of prostate cancer recurrence frequently requires several high PSA tests. Since a high PSA level can be caused by a variety of factors, the majority of medical professionals wait until there have been at least two consecutive increases in PSA before concluding that prostate cancer is likely to return.

Recurrent Prostate Cancer (Epidemiology)

The third most frequent cancer is prostate cancer. It is an extremely diverse illness, with a global incidence of 6 to 83 per 100,000 people. South-Central Asia has the lowest age-standardized incidence rates while Northern Europe has the highest rates. The disease is more contagious in African-American men than in people of other races. The highest mortality and infection rates are found in the Caribbean, sub-Saharan Africa, and Micronesia/Polynesia. Global incidence (112 of 185) and incidence in high HDI and low HDI countries were very different, coming in at 11.3 and 37.5 per person, respectively. 100 thousand people. Less variation was seen in mortality rates (5.9 vs. 8.1 out of 100,000). With an incidence ranging from 6 to 83 per 100,000 people worldwide, prostate cancer is a heterogeneous disease. The Caribbean, Australia/New Zealand, North America, South Africa, Northern and Western Europe, and Australia/New Zealand are the regions with the highest percentage. The rates are lowest in Asia and North Africa. The incidence of this cancer has historically been low in Asian nations like Japan and Singapore, where prostate-specific antigen (PSA) testing is insufficient, but the number of cases is rising in these nations. The highest rates of mortality and infection are found in the Caribbean (75.8 per 100,000 people), sub-Saharan Africa (22.0 per 100,000 people), and Micronesia/Polynesia (18.8 per 100,000 people).

Recurrent Prostate Cancer -Current Market Size & Forecast Trends

The market for recurrent prostate cancer (rPC) is expected to experience substantial growth in the coming years. The castrate-resistant prostate cancer (CRPC) segment, which includes rPC, was valued at approximately USD 12.92 billion in 2024 and is projected to grow to around USD 29.79 billion by 2034, reflecting a compound annual growth rate (CAGR) of 8.7% during this period. The increasing prevalence of prostate cancer, particularly among older populations, is driving demand for effective treatments as more patients transition to CRPC and rPC stages. Additionally, advancements in therapeutic options, including novel targeted therapies and immunotherapies, are expected to enhance treatment outcomes and further stimulate market growth. The U.S. is anticipated to dominate the market due to its advanced healthcare infrastructure and ongoing innovations in drug development. Overall, the recurrent prostate cancer market is well-positioned for significant expansion through 2035 as new therapies continue to emerge and improve patient care.

The most typical radiation treatment for prostate cancer recurrence is external radiation therapy. Hormonal therapy may be combined with it. Radiation therapy may be used to treat prostate cancer that has undergone surgical resection but returned to the same site. External beam radiation cannot be applied to the same area of a cancer that has already received this treatment. This is because radiation can cause significant harm to the bladder and rectus-two organs that surround the prostate. A radioactive substance (radioisotope) implanted into or very near the tumor is used in the radiation therapy procedure known as brachytherapy. If external beam radiation therapy was used to treat a prostate tumor initially and the cancer has not spread to other body parts, brachytherapy may be suggested to treat a recurrence. After surgery or radiation therapy, prostate cancer that returns may be treated with hormone therapy (also known as androgen deprivation therapy). Prostate cancer that returns outside of the prostate area is primarily treated with it. To stop the growth and spread of cancer cells, it lowers hormone levels or blocks specific hormones. Both alone and in conjunction with radiation therapy, hormone therapy is an option. If one hormone therapy is ineffective, a different one might be tried. Rarely is surgery used to treat recurrent radiation-treated prostate cancer. Using extremely low or even freezing temperatures, a procedure known as cryosurgery can eliminate abnormal cells or tissue. Sometimes, recurrent prostate cancer is managed with radiation therapy as the initial therapy. If the patient is unable to undergo surgery or radiation therapy because of additional medical issues, cryosurgery may be used. High Intensity Focused Ultrasound (HIFU) uses focused ultrasound to produce intense heat in order to kill cancer cells. HIFU is presently being tested as a prostate cancer treatment. It is occasionally used by doctors to treat prostate cancer that returns following radiation therapy. When prostate cancer has returned outside the prostate, chemotherapy may be advised. To eradicate cancer cells, anticancer medications are used. Docetaxel and prednisone are the two drugs that are used the most. They are utilized in conjunction with hormonal therapy. To stop the growth and spread of cancer and minimize damage to healthy cells, targeted therapy employs medications that specifically target particular molecules, such as proteins, on or inside cancer cells. When recurrent prostate cancer has specific genetic mutations, targeted therapy may be used to treat it.

Report Highlights

Recurrent Prostate Cancer - Current Market Trends

Recurrent Prostate Cancer - Current & Forecasted Cases across the G8 Countries

Recurrent Prostate Cancer - Market Opportunities and Sales Potential for Agents

Recurrent Prostate Cancer - Patient-based Market Forecast to 2035

Recurrent Prostate Cancer - Untapped Business Opportunities

Recurrent Prostate Cancer - Product Positioning Vis-a-vis Competitors' Products

Recurrent Prostate Cancer - KOLs Insight